The UCLA Prostate Cancer SPORE is a multidisciplinary and translational research program focused on the development of new and innovative approaches for improving the diagnosis, prognosis, and treatment of prostate cancer patients. The program?s reach includes collaborating investigators at local institutions such as Cedars Sinai and City of Hope in order to accelerate the goal of combating prostate cancer. A particular strength of the UCLA Prostate Cancer SPORE has been its ability to leverage institutional and NCI support to attract new human capital, technology, and ideas to the field of prostate cancer. Examples of these discoveries include: (1) the development of both the androgen receptor (AR) super-antagonists enzalutamide and apalutamide, (2) the discovery of the putative human prostate cancer stem cell of origin and its association with emergence of the lethal neuroendocrine phenotype, (3) the translation of novel engineered antibodies targeting Prostate Stem Cell Antigen (PSCA) to the clinic to target, treat and image prostate (and pancreatic) cancer, (4) the elucidation of signaling cross-talk between the PTEN/PI3K, AR, and ras/MAPK pathways in castrate resistant and treatment resistant prostate cancer (CRPC), and (5) the demonstration that a low fat diet supplemented with omega-3 fatty acids has measurable effects on prostate cancer and its mechanism of action. The overall goal of this competitive renewal application is to continue to apply the diversity of talent on the UCLA campus, its sister institutions and other institutions in Southern California to the critical and evolving translational challenges in the field of prostate cancer. To achieve the long-term objectives and goals of our program, the Specific Aims of the UCLA SPORE in Prostate Cancer are: (1) to perform high-impact translational research focused on some of the major challenges in the field of prostate cancer such as cancer metastasis, castration resistance, and treatment resistance, (2) to provide organizational infrastructure and novel technologies designed specifically to support the translational research objectives of the SPORE such as administrative, fiscal, and statistical support, and (3) to develop new prostate cancer researchers and research areas to advance translational research in prostate cancer through supporting innovative research in critical areas, pilot developmental research, and career development in prostate cancer research. Through these aims, UCLA Prostate Cancer SPORE can continue to promote significant and novel discoveries with potential major impact on men with prostate cancer.

Public Health Relevance

Prostate cancer is a major cause of morbidity and mortality in the US. The goal of our Prostate Cancer SPORE is to apply basic laboratory research to the goal of preventing, managing and curing all forms and stages of this disease. This will be accomplished through 4 major projects focused on critical unmet needs in this disease, pilot and developmental research programs, and core infrastructure support of research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-17
Application #
10000832
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Arnold, Julia T
Project Start
2002-09-15
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
17
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Urology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Lee, Ha Neul; Mitra, Mithun; Bosompra, Oye et al. (2018) RECK isoforms have opposing effects on cell migration. Mol Biol Cell 29:1825-1838
Aggarwal, Rahul; Huang, Jiaoti; Alumkal, Joshi J et al. (2018) Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol 36:2492-2503
Cheng, Larry C; Li, Zhen; Graeber, Thomas G et al. (2018) Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer. J Vis Exp :
Park, Jung Wook; Lee, John K; Sheu, Katherine M et al. (2018) Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95
Tan, Nelly; Shen, Luyao; Khoshnoodi, Pooria et al. (2018) Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. J Urol 199:1218-1223
Donin, Nicholas M; Reiter, Robert E (2018) Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med 59:177-182
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82

Showing the most recent 10 out of 339 publications